Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of metastatic colorectal cancer with a Ras mutation~* Measurable or evaluable disease~* No prior therapy fore metastatic disease except for group A: \> 6 months since completion of adjuvant therapy and Group B: those patients who enroll just after completing bevacizumab plus FOLFOX or FOLFIRI~* Anticipated survival of at least 6 months~* Ambulatory with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Ability to maintain weight~* Normal organ and marrow function~* Women of child-bearing potential and men must agree to avoid pregnancy or fathering a child for the duration of study participation and for 6 months after the final scheduled study visit.~* Ability to understand and willingness to sign a written informed consent document~Exclusion Criteria:~* Prior chemotherapy other than that listed in inclusion criteria~* Receiving any other investigational agent~* Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis~* History of known hypersensitivity to S. cerevisiae, bevacizumab or any component of FOLFOX or FOLFIRI~* Concurrent and chronic therapy with corticosteroids or any other immunosuppressive drugs~* Uncontrolled hypertension, unstable angina, congestive heart failure, peripheral vascular disease, serious cardiac arrythmias requiring medication~* History of heart attack or stroke within 6 months before enrollment~* History of intra-abdominal abscess, abdominal fistula, gastrointestinal perforation, or active peptic ulcer disease~* Bleeding disorder or coagulopathy~* Serious non-healing wound, ulcer or bone fracture~* Major surgical procedure, open biopsy, or traumatic injury within 4 weeks prior to enrollment or anticipation of need for surgery during the study~* Known active infection with HIV, hepatitis B or C~* History of splenectomy~* History of Crohn's disease or ulcerative colitis~* History of organ transplantation~* Evidence of immunodeficiency or immune suppression~* Any Autoimmune disease~* Active infection~* Concurrent malignancy~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy and GI-4000 (Type: EXPERIMENTAL): Standard chemotherapy and bevacizumab 40 yeast units (YU) GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks
- GI-4000 and bevacizumab (Type: EXPERIMENTAL): maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues